
Opinion|Videos|July 23, 2026 (Updated: July 16, 2026)
Defining Alzheimer's Disease Agitation: Diagnostic Criteria, Symptoms, and Disease Course
Kavita Nair leads the discussion on defining Alzheimer's disease agitation.
Advertisement
Episodes in this series

Kavita Nair leads the discussion on defining Alzheimer's disease agitation. Anton Porsteinsson outlines IPA provisional diagnostic criteria (2015, made permanent 2023): agitation must occur in context of cognitive impairment, include ≥1 of 3 behavioral manifestations (excessive motor activity, verbal aggression, physical aggression), persist ≥2 weeks, cause distress and disability, and not be attributable to another condition. Agitation can present as early as pre-dementia stages (MCI) and typically peaks during moderate to early severe stages.
Advertisement
Related to this article

Michael Mina, MD, PhD, explains which adverse events drove VYD2311's edge vs an mRNA COVID-19 vaccine and who may benefit most.

Panelists engaged in a debate regarding using complement inhibitors in geographic atrophy, gauging public sentiment with a deciding vote.

A session at AAO 2026 highlighted how big data and minimally invasive glaucoma surgery (MIGS) could be utilized to help patients receive peak care.

Medicaid expansion was associated with lower colorectal cancer mortality, with the largest reductions in Hispanic patients and stage IV disease.

Cepheid's Connie Savor, MD, MBA, explains where its 13-pathogen respiratory panel fits in diagnostic stewardship and antibiotic decisions.

The FDA approves atezolizumab with a fluoropyrimidine and oxaliplatin as adjuvant therapy for stage III dMMR colon cancer based on the ATOMIC trial.

Michael Mina, MD, PhD, explains Invivyd's accelerated approval path for VYD2311 and how it could change the timing of COVID-19 protection.
Advertisement
Advertisement
Trending on AJMC
1
MASH Fibrosis, Not Resolution, Predicts Mortality: Zobair Younossi, MD
2
5 Things to Know if Retatrutide Is Classified as a Biologic
3
FDA Approves Once-Monthly Subcutaneous Olanzapine for Schizophrenia
4
Full POLARGO Data Reveal OS, Safety for Pola-R-GemOx in DLBCL
5

